KLOW
GHK-Cu + BPC-157 + TB-500 + KPV blend
KLOW (GHK-Cu + BPC-157 + TB-500 + KPV blend) is a blends & other research compound. GLOW plus KPV — recovery and skin remodeling with an added anti-inflammatory arm from KPV.
KLOW quick facts
| Reported research dose | 1-3mg GHK-Cu & 200-600mcg BPC,TB,KPV |
| Route | Subq |
| Frequency | 1x Daily · 5 On 2 Off or Daily |
| Half-life | Varies by component |
| Forms | Injectable |
| Evidence level | Anecdotal (blend) |
GLOW with an anti-inflammatory upgrade. One draw, broad recovery.
How KLOW works
GLOW plus KPV — recovery and skin remodeling with an added anti-inflammatory arm from KPV.
Proposed benefits
A combination formula — proposed benefits reflect the sum of its individual components.
Where to get KLOW
KLOW is sold in 3 forms. They are not interchangeable — the dose and the route differ, so pick the one this page describes unless you know why you want another.
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for KLOW
Graded by what exists behind each claim.
✅ Clinically validated
- No trial of the blend. KLOW is a compounded combination of GHK-Cu, BPC-157, TB-500 and KPV — read each component's clinical tier; the blend inherits their evidence and adds none of its own.
📊 Correlative data
- GLOW with KPV added, used where inflammation is part of the picture rather than pure repair. Reported experience is correspondingly broader.
- Same trade-off as any fixed blend: no ability to titrate one component without moving the rest.
🧪 Theoretical / extrapolated
- Four mechanisms in one vial — copper delivery and gene expression (GHK-Cu), angiogenesis (BPC-157), cell migration (TB-500) and NF-κB inhibition (KPV).
- KPV is the reason to choose this over GLOW: the other three all promote growth and vascularization, and KPV is the only one damping inflammation. That is a genuine mechanistic complement rather than more of the same.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What KLOW actually does
Four components, and the one that decides how the vial behaves is the only one that is not a peptide. It is a metal complex.
GHK-Cu is copper(II) held by a tripeptide. Gly-His-Lys coordinates the metal through the N-terminal amine, the imidazole nitrogen of the histidine and the deprotonated backbone amide between them; the geometry and the donor atoms have been examined computationally Alshammari 2020, and the peptide's biology has been reviewed against the gene-expression data Pickart 2018. Everything else in the vial is a plain peptide with no metal.
KPV is the most interesting component and the one whose mechanism is most often mis-stated. It is Lys-Pro-Val, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone — the same parent hormone that the melanocortin agonists elsewhere in this Vault are built from. But KPV does not contain the His-Phe-Arg-Trp message sequence that melanocortin receptors recognize. Work dissecting the anti-inflammatory effect of the core and the C-terminal KPV region of alpha-MSH separated those two activities directly Getting 2003. So KPV is an anti-inflammatory fragment of a melanocortin hormone that is not a melanocortin receptor agonist — it acts inside the cell, on NF-kappaB signaling, rather than at a surface receptor.
And that changes what route makes sense for it. KPV's best-characterized mechanism is uptake by PepT1, the di-/tripeptide transporter of the intestinal brush border: PepT1-mediated KPV uptake reduced intestinal inflammation Dalmasso 2008, it had anti-inflammatory potential in murine colitis models Kannengiesser 2008, and the delivery work built on it is oral, using hyaluronic-acid-functionalized nanoparticles to target the tripeptide to inflamed gut Xiao 2017. The route with the evidence for KPV is luminal. This product injects it.
The other two are the repair pair. BPC-157's literature is a rat cytoprotection literature across tendon, muscle, ligament and bone Staresinic 2022; TB-500 is the actin-binding heptapeptide of thymosin beta-4, one of several activities that map to different short sequences within the parent protein Sosne 2010.
The chemistry question a four-peptide copper vial raises, answered rather than waved at. Copper(II) catalyzes oxidation of susceptible amino acid side chains — methionine, cysteine, histidine and tryptophan are the vulnerable ones. Reading the three co-formulated sequences: Lys-Pro-Val contains none of them, the thymosin heptapeptide Leu-Lys-Lys-Thr-Glu-Thr-Gln contains none of them, and BPC-157's pentadecapeptide sequence contains no cysteine, methionine, histidine or tryptophan either. So the obvious oxidation hazard is largely absent here, and this page will say so rather than invent a risk. What remains is competition: the carboxylate-rich residues in the other peptides are weak copper ligands, and weak ligands in large molar excess still shift a coordination equilibrium.
Cell, rodent, human — and where it stops
Step one, cells and biochemistry, component by component. GHK's copper coordination modeled Alshammari 2020 and its gene-expression biology reviewed Pickart 2018; the anti-inflammatory activity of the alpha-MSH C-terminal tripeptide dissected from the core Getting 2003; the actin-binding activity of the thymosin fragment placed among the parent protein's other activities Sosne 2010.
Step two, rodents. KPV reduced intestinal inflammation through PepT1-mediated uptake Dalmasso 2008 and showed anti-inflammatory potential in murine colitis Kannengiesser 2008; oral nanoparticle delivery of KPV to inflamed gut was developed on that basis Xiao 2017. BPC-157's tissue-repair results are rat results across several injury models and several routes Staresinic 2022.
Step three, humans — and here the four components part company completely. There is no randomized human trial of this blend. There is no randomized human efficacy trial of BPC-157 for a musculoskeletal indication. There is no human trial of injected KPV. The human work in this family belongs to the intact thymosin beta-4 protein rather than to the heptapeptide Sosne 2010, and to topical copper-peptide cosmetics rather than to injected GHK-Cu Pickart 2018.
The obstacle that is specific to this product rather than to its parts: the copper arithmetic. GHK-Cu has a formula mass near 400 and copper accounts for roughly 16% of it. A 3 mg dose therefore delivers about 0.47 mg of elemental copper, and a 1 mg dose about 0.16 mg. For comparison, typical daily dietary copper intake is around 1 mg with roughly a third to a half absorbed — so a 3 mg daily dose of the copper peptide is comparable to or greater than the amount of copper a person normally absorbs in a day, delivered past the intestine, which is the site where copper absorption is regulated. Over a 12-week daily course that is on the order of 40 mg of copper entering the body without passing the control point.
And the second product-specific obstacle: four components mean four failure modes and no way to isolate one. Nothing in the literature above tested any two of these together, let alone all four, and a blend inherits its components' evidence only under the assumption that they do not interact — an assumption that the copper makes harder to justify here than in a peptide-only mixture.
KLOW pharmacokinetics — how much of it actually gets in
The card says varies by component, and for this product the components differ not just in speed but in kind: three peptides cleared by proteolysis and one metal whose fate is decided by ligand exchange.
The peptides. All three are linear, unmodified and exposed at both termini, so serum and tissue aminopeptidases and endopeptidases are the whole clearance route. A tripeptide goes fastest, the heptapeptide next, the pentadecapeptide slowest — a spread of roughly an order of magnitude across the vial. None is a cytochrome substrate and none has a meaningful hepatic metabolism story.
The copper is on a different clock entirely. Ligand exchange between copper complexes is fast, and plasma contains albumin and ceruloplasmin, both of which bind copper — albumin through an N-terminal site of its own. Extrapolated from coordination chemistry and labeled as such: the tripeptide-copper complex should begin to hand its metal over on a timescale far shorter than the peptide's own proteolytic half-life Alshammari 2020, which means what circulates after an injection is largely free tripeptide plus protein-bound copper, and not the complex that was studied. Nobody has measured this for GHK-Cu in human serum.
The oral question splits the vial in two. KPV has a genuine oral argument, because PepT1 is an intestinal transporter and the published work uses it deliberately Dalmasso 2008Xiao 2017; a tripeptide taken by mouth can reach the enterocyte intact. The other three do not have that argument — the heptapeptide and pentadecapeptide are too long for PepT1, which carries di- and tripeptides only, and gastric acid will strip copper from the tripeptide before it reaches the duodenum. So an oral version of this blend is one working ingredient and three passengers, and an injected version is three ingredients delivered by their studied route and one — KPV — delivered by a route that bypasses its own published mechanism.
The steady-state consequence. With clearance times spread across an order of magnitude and one component's active form dissociating in the bloodstream, the ratio in the body is never the ratio in the vial at any point after the first few minutes. That is not an argument that the product does nothing; it is an argument that the number printed on the label describes the syringe and not the person.
What would have to be true, and how you would know it was not
Three predictions with markers and windows. The first two are copper measurements; the third argues that one quarter of this product is being given by the wrong route.
1. Serum copper and ceruloplasmin should be checked, and the gap between them is the informative part. Roughly 0.47 mg of copper per 3 mg dose, delivered parenterally, is a meaningful addition to daily copper entry. Prediction: copper and ceruloplasmin at baseline and at 12 weeks stay within range on intermittent dosing; on daily dosing, serum copper rises while ceruloplasmin does not, because ceruloplasmin synthesis is not substrate-driven on that timescale. A rising copper with a flat ceruloplasmin is loosely bound copper, and that is the fraction with oxidative potential.
2. Plasma zinc should fall before serum copper rises. Copper and zinc compete in absorption and in metallothionein handling, and copper is homeostatically defended while zinc is the one that yields. Prediction: plasma zinc at baseline and 12 weeks drifts downward on a sustained course. It is the more sensitive of the two markers and it costs the same.
3. Against the product: KPV given by injection should underperform KPV given by mouth for a gut indication, and that is a clean falsifiable claim. Its published mechanism is PepT1-mediated uptake at the intestinal brush border, demonstrated as a reduction in intestinal inflammation Dalmasso 2008, reproduced in murine colitis Kannengiesser 2008, and built on with an oral targeted delivery system Xiao 2017. A subcutaneous injection puts the tripeptide into the bloodstream and past the transporter its evidence runs through. Prediction: for gut inflammation, an oral KPV dose beats the same milligram amount injected, measured by hs-CRP and by symptom frequency over 8 weeks. If the injected route matches it, then KPV has a systemic mechanism nobody has characterized, which would be worth knowing on its own.
What nobody has tested yet
Four things unmeasured for this specific combination.
Whether the copper stays on the peptide once it is in blood. This is the first question for any injected copper complex and it has never been answered experimentally — incubation in human serum with copper speciation over time would do it Alshammari 2020.
Whether the copper interferes with the other three. The oxidation-prone residues are absent from all three co-formulated sequences, which removes the obvious hazard — but weak carboxylate coordination in a mixture at millimolar concentrations has not been examined for this combination. Mass spectrometry of a reconstituted vial at day 1 and day 30 would answer both stability questions at once.
Whether KPV does anything at all outside the gut. Its human-relevant mechanism is intestinal Dalmasso 2008Xiao 2017 and its anti-inflammatory activity was defined against the receptor-binding core of the parent hormone Getting 2003. What a systemically injected tripeptide does to a tendon, which is what this blend is used for, has not been studied in any species.
Whether four components beat three. The stated reason to choose this over the three-component version is the anti-inflammatory arm. That is a testable claim — same three peptides with and without KPV, one injury model, one inflammatory readout — and no such comparison exists.
KLOW — its own safety story, not its class's
The specific risk of this product is copper delivered past the step that normally regulates it, repeated daily.
The number, so it is not abstract. About 0.16 mg of elemental copper per 1 mg of the copper tripeptide, about 0.47 mg per 3 mg. Daily dosing at the top of the range is comparable to a full day's normal copper absorption, added on top of diet, and bypassing the intestinal control that would otherwise reduce uptake when stores are adequate. A four-to-twelve-week course at that rate is tens of milligrams of parenteral copper.
Who must not use this is defined by genetics. Wilson disease impairs copper excretion, and the people who have it frequently do not know until something forces the question. A ceruloplasmin and a serum copper before starting is the whole screen, and it is the one pre-flight test this blend genuinely earns.
Zinc is the marker that moves first in a healthy person. Sustained copper loading lowers zinc through shared absorption and metallothionein handling long before copper itself exceeds range, and low zinc has its own consequences for immunity, taste and skin — several of which overlap with what the product is taken for.
The attribution problem is worse here than in a two-component blend. Four active ingredients and one preservative means five candidates for any effect, and there is no titration path that moves one without moving the others. A person who reacts to the copper cannot keep the repair peptides; a person who wants more of the anti-inflammatory arm has to take more copper to get it. That is the cost of the format and it is paid whether or not the ingredients work.
And the angiogenesis caution that applies to three of the four. Copper is a cofactor for angiogenesis, BPC-157's repair mechanism includes new vessel formation Staresinic 2022, and the thymosin fragment accelerates cell migration Sosne 2010. Nothing published shows that any of them promotes tumor growth in a person, and nothing shows that they do not, because the studies do not exist. For anyone with an active or recent malignancy the honest answer is that the question is open rather than reassuring.
Sources read for this page
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci 2018 · PMID 29986520
- Alshammari N, Platts JA. Theoretical study of copper binding to GHK peptide. Comput Biol Chem 2020 · PMID 32371360
- Getting SJ, et al. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. Journal of Pharmacology and Experimental Therapeutics 2003 · PMID 12750433
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008 · PMID 18061177
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases 2008 · PMID 18092346
- Xiao B, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular Therapy 2017 · PMID 28143741
- Staresinic M, et al. Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Biomedicines 2022 · PMID 36551977
- Sosne G, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB Journal 2010 · PMID 20179146
KLOW — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- KLOW is four peptides — GHK-Cu, BPC-157, TB-500 and KPV. Three are repair peptides pulling the same way; the fourth is a copper carrier, which is why the copper cautions apply here and would not to a plain healing stack.
- *the GHK-Cu arm:* The copper is the active ingredient and also the constraint. Copper is an essential trace mineral with a genuine upper limit, and these deliver it directly.
- *the GHK-Cu arm:* Topically over a small area this is not a systemic concern. Large surface areas, high concentrations, or injecting it are a different proposition — the same molecule at a different exposure.
- *the BPC-157 / TB-500 / KPV arms:* Repair peptides work by promoting angiogenesis — new blood vessel growth — plus fibroblast migration and growth-factor signaling. That is what makes them useful, and it is the entire basis of the one theoretical concern worth naming: angiogenesis is also what a tumor needs to grow beyond a few millimetres.
- *the BPC-157 / TB-500 / KPV arms:* There is no evidence these compounds cause or accelerate cancer. There is a mechanistic reason not to run a pro-angiogenic agent systemically with an active or recently treated malignancy, and that reasoning stands without a trial.
- *the BPC-157 / TB-500 / KPV arms:* The second predicted issue is more mundane and more likely: they can mask a signal. Something that reduces pain and inflammation around an injury lets you load a tissue that has not finished healing.
- The risk that belongs to the blend rather than any component: double-dosing. If you already run any of the peptides above separately, adding this blend means two doses of it — and almost nobody counts a blend's arms against what is already in their protocol. Read the composition against your current stack before the first injection.
What has actually been reported
- *the GHK-Cu arm:* Topical use is well tolerated; irritation and temporary blue-green staining are the common complaints, both cosmetic.
- *the BPC-157 / TB-500 / KPV arms:* Very well tolerated in reported use. Injection-site reactions and transient light-headedness are the common complaints.
- *the BPC-157 / TB-500 / KPV arms:* Human data is thin — most of the literature is rodent — so 'well tolerated' here means 'no signal has emerged from a lot of informal use', which is weaker than a clean trial and stronger than nothing.
How to reduce the risk
Same mechanism as the prediction.
- *the GHK-Cu arm:* Match the exposure to the goal. A face-sized area of a topical is a different proposition from full-body use or injection. Most of the cosmetic benefit is local, so there is rarely a reason to escalate to systemic exposure for a skin outcome.
- *the GHK-Cu arm:* Keep it away from direct vitamin C in the same layer. Copper and ascorbic acid deactivate each other — this wastes both rather than harming you, but it is the most common way people get nothing from an expensive product. Vitamin C in the morning, copper at night.
- *the GHK-Cu arm:* Don't stack multiple copper products at once. A copper serum, a copper shampoo and a copper body lotion are three doses of the same mineral, and the ceiling is on the mineral, not on the product.
- *the GHK-Cu arm:* If you are injecting it or covering large areas long-term, serum copper and ceruloplasmin are the two markers that would actually show accumulation.
- *the BPC-157 / TB-500 / KPV arms:* Stop when the thing you were treating has resolved. There is no mechanism here that demands a clock, and equally no reason to keep running a pro-angiogenic signal once the job is done.
- *the BPC-157 / TB-500 / KPV arms:* Do not let reduced pain set your training load. The tissue heals on its own timeline whether or not you can feel it. Reloading early on the strength of feeling better is the most common way people turn a good result into a re-injury.
- *the BPC-157 / TB-500 / KPV arms:* Get the diagnosis before the peptide. These accelerate healing of things that heal. A tear that needs surgical repair does not become a tear that does not, and the delay costs you.
- *the BPC-157 / TB-500 / KPV arms:* One injury, one compound, long enough to judge it. Otherwise you learn nothing transferable for next time.
What it does to your bloodwork
A fact about the assay.
- *the GHK-Cu arm:* If you are using this at scale or injecting it, serum copper and ceruloplasmin are the markers that would show accumulation.
- *the BPC-157 / TB-500 / KPV arms:* Nothing routine tracks these directly. The endpoint is the injury, which means your own honest assessment of function is the measurement.
Don't run this if
- *the GHK-Cu arm:* Wilson's disease or any condition of copper handling — the mechanism is delivering the exact thing you cannot clear.
- *the BPC-157 / TB-500 / KPV arms:* Active or recently treated malignancy — the angiogenesis reasoning.
- *the BPC-157 / TB-500 / KPV arms:* Any undiagnosed lump or lesion. Find out what it is first.
The honest unknown
- *the GHK-Cu arm:* Cumulative copper load from long-term high-surface-area topical use has not been characterized.
- *the BPC-157 / TB-500 / KPV arms:* Long-term systemic exposure in humans has never been characterized. The use case is naturally self-limiting — you stop when the injury resolves — which is why this matters less here than it would elsewhere.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
KLOW — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What KLOW moves on your bloodwork
Expected direction, not a measured one.
- Copper, Serum — ↑ expected to rise
From the GHK-Cu arm. Only relevant at systemic doses — topical use does not meaningfully raise serum copper.
What to do: Not routinely needed. It matters if you are injecting it regularly or already have a copper-handling condition. - Ceruloplasmin — ◆ worth watching
From the GHK-Cu arm. The copper-carrying protein, and the one that tells you whether copper is bound and safe or free and reactive.
What to do: Read with serum copper, never alone. - Zinc, Plasma — ↓ expected to fall
From the GHK-Cu arm. Copper and zinc compete for absorption. Sustained copper loading predicts falling zinc, which then shows up as immune and taste changes that get blamed on something else.
What to do: If you are running copper systemically for months, check zinc. - hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
From the BPC-157 / TB-500 / KPV arm. If a repair peptide is doing anything systemic, inflammation is where it would plausibly show.
What to do: Worth a baseline if you are running one for a chronic issue rather than an acute injury. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
From the BPC-157 / TB-500 / KPV arm. Standard baseline. Nothing in this class predicts a specific abnormality — which is itself worth saying rather than inventing one.
What to do: Annual is fine unless something changes.
KLOW is four peptides: GHK-Cu, BPC-157, TB-500 and KPV. Three of them are repair peptides pulling in the same direction, and the fourth is a copper carrier — which is why the copper notes apply here and would not to a plain healing stack. If you are already running BPC-157 or TB-500 separately, you are doubling those arms, and most people running KLOW alongside a healing protocol have not counted that.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Storage and travel
- How the forms differ in dose
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — KLOW in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside KLOW
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Comprehensive Metabolic Panel (CMP) | Liver, kidney, electrolytes and glucose in one |
| Complete Blood Count (CBC) with Differential | Broad screen for anything unexpected |
| hs-CRP (High-Sensitivity C-Reactive Protein) | Inflammation baseline |
The Basics — Start Here panel covers these in one order — 4 markers, $32.40 with the discount applied.
Check results you already have → · All 103 markers A–Z
KLOW — frequently asked questions
What is KLOW?
KLOW (GHK-Cu + BPC-157 + TB-500 + KPV blend) is a blends & other research compound. GLOW plus KPV — recovery and skin remodeling with an added anti-inflammatory arm from KPV.
Is the full KLOW protocol on this page?
The reported research dose is on this page, along with how KLOW works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of KLOW?
KLOW has an approximate half-life of Varies by component, which is part of what determines how often it's dosed.
What's the evidence behind KLOW?
Current evidence level: Anecdotal (blend). KLOW is offered for research purposes only and is not an approved medicine.
What KLOW is used for
KLOW appears under 1 goal in the goal router.
Related Blends & Other compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.